

PRESS RELEASE

Extended Wear Time: SpeedM® may now remain in the wound for up to 72 hours

Neubrandenburg, September 23, 2026 – The SpeedM® emergency hemostatic dressing now meets a new key market requirement: Instead of the previous 24 hours, the product may now remain in the wound area for up to 72 hours before further treatment is required.

A response to real-world field conditions

This extension addresses specific challenges of prolonged field care, as highlighted in particular by recent experiences in Ukraine: When rapid follow-up treatment is not possible, initial care must remain safe and effective even over an extended period. With the new 72-hour approval, SpeedM® addresses precisely this reality and significantly improves on-site medical care during the so-called “72-hour triduum.” The approval was based on a comprehensive reassessment of the product’s biocompatibility data.

“With the approval of the 72-hour retention period, we are responding swiftly to an important market need and making a significant contribution to patient safety in emergency situations where rapid follow-up care is often not possible,” explains Ulf Pommerening, Managing Director.

Safety Through Material Design—Highly Effective Mineral and Technological Expertise

The special composition of SpeedM® offers additional safety: The dressing is based on the innovative mineral halloysite. Thanks to a patented manufacturing process, the hemostatic components are firmly bonded to the dressing’s carrier matrix and cannot detach—a safety feature that makes SpeedM® ideal even for prolonged use in the wound.

Transitional Regulations During the Transition Period

The product labeling for SpeedM® currently still indicates a maximum dwell time of 24 hours. During the transition phase, products with both the previous labeling (24h) and the updated labeling (72h) will be distributed—both versions are approved and refer to the same product specification and the same intended use. The transitional arrangement will remain in effect until existing packaging materials are depleted and production has fully transitioned to the new labeling.

The extension of the retention period thus underscores both Speed Care Mineral’s swift adaptation to market requirements and the high priority it places on patient safety.

About Speed Care Mineral GmbH

Speed Care Mineral has developed a production process that permanently and safely applies the hemostatic mineral halloysite to a non-woven cellulose matrix, ensuring that no minerals remain in the wound.

The SpeedM® product is a third-generation mineral hemostatic device that combines performance, safety, control, and speed at a very high level.

Press Contact:

Siegfried Kruse
Managing Director
Speed Care Mineral GmbH
info@speedcaremineral.de

SCM2026046 Rev00 September 2026